Blog | Contact Us

A directional test for tumour profiling enabling oncologists to predict response/ resistance to targeted and immuno-therapies for cancer patients over the traditional molecular testing. It assists in predicting outcomes of FDA approved drug responses for approved biomarkers and treatment management.

Official Analytics partner

(Developed the first FDA approved Cancer Companion Diagnostic Test)

The world’s oldest and largest private cancer center, and GenePower(by K&H), partnered into collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors along with K&H proprietary database to provide accurate recommendations for Indian population .

Highlights

A directional test for tumor profiling enabling oncologists to predict response/ resistance to targeted and immuno-therapies for cancer patients over the traditional molecular testing.

Over 5600 genomic alterations covered-
We report substitutions, insertions, deletions, CNV, select rearrangements as well as genomic signatures including microsatellite instability and tumor mutation burden
We are the only company in Genomics space

lead by physicians in India.

Simplified reports
without ambiguous reporting is possible because we know exactly what a treating physician is looking for in the report
Open Discussion channel

between Oncologist, Pathologist and genomic specialist physician will lead to best treatment choices for the patient.

GenePower OncoRx uses targeted genomic sequencing and analysis to provide the physician with information on-

  • Druggable mutations in your patient for which targeted
    therapies are available.
  • Clinical trial match connector
  • Microsatellite Instabilty status (MSI)
  • Tumor Mutational Burden status (TMB)
  • Sample required- FFPE tissue sample
  • TAT(Turn Around Time)- 3- 4 weeks

Testing steps

Next gen sequencing using Illumina NovaSeq sequencerIn house developed Bioinformatics algorithms for data analysisFinal report generation using Databases in association with MSK Cancer hospital

We offer

Biomarkers:

Screens over 353 potential genes -174 suitable for characterizing cancer biomarkers with proven clinical utilities and an additional 179 high-confidence cancer genes which have emerging evidence in the recent ongoing clinical trials.

Patients with stage 3 or stage 4 cancer who are looking to start targeted drug therapy.

When a patient is first diagnosed with cancer, it is suggested to take OncoRx test, prior to starting their chemotherapy treatment. The test enables the physician to identify the right drug regimen from the various FDA approved therapies. The response and management of the regimen is also analysed from the report enabling better decision-making for physicians.

OncoRx is India’s only test authenticated by FDA approved database developed by collecting longitudinal data over 20 years by clinicians/oncologists from MSK- Memorial Sloan Kettering Cancer Centre

Being the only company to be led by clinicians, we provide simple and ambiguous reports that the clinicians are looking for when treating a patient. While maintaining precision in performance standards, decryption of data and quality control, the reports are automated with minimal turn-around-time.

OncoRx is testing solid tumours that uses next generation sequencing (NGS) to detect the four alterations known to drive cancer growth:

  1. SNP
  2. InDels (Insertions and Deletions)
  3. Copy number Variants (CNVs)
  4. Rearrangements or fusions

FAQs

A:  Targeted therapies act on specific molecular targets associated with cancer which have proven evidence for the desired response and predicted outcomes. Standard chemotherapy on the other hand, act on rapidly diving normal and cancerous cells.

A: Onco mini test aids physicians for oncotherapy decision making by screening a short panel with 71 cancer genes covering:

Level 1- FDA approved drugs for FDA approved biomarkers

Level 2- NCCN ratified standard care biomarker response to FDA approved drugs

R1 candidate genes - Standard care bio-markers with resistance to FDA approved drugs

 

It is generally recommended for a patient who is opting for chemotherapy.

 

OncoRx Test screens a large panel of over 353 potential genes assisting in predicting outcomes of FDA approved drug response, resistance, immunotherapy selection and management. The biomarkers covered are:

Level 1, Level 2 and Level 3 (Biomarkers with compelling clinical evidence to FDA approved or investigational drugs )

 

 If a patient were to develop resistance of the ongoing chemotherapy it is recommended to choose OncoRx.

OncoRx is authenticated through collecting the world’s only FDA approved database which is developed by collecting real-time authorised data over 20+ years from Clinicians/ Oncologists of MSK. OncoRx also provides partnership opportunities to develop concrete databases, and 24/7 customer care representatives.

OncoRx provides the best second-line options for the patients as per the NCCN guidelines. We also provide clinical trial matches for the patients to enrol in leading institutions globally.

Single marker or Hotspot Mutation testing can detect only one alteration wherein OncoRx can provide insights on all four alterations known to drive cancer growth. The method of testing, therefore, takes a comprehensive approach to diagnosis and detailed reporting.

The biomarkers for non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, prostate cancer and all solid tumours are covered in the test. After identifying the specific biomarkers, the targeted FDA- approved therapies are selected.

An initial quality measure is performed in 3 days and processed only if the sample meets the OncoRx standards.

Helping us to deliver precise reports